AURA
Price
$6.43
Change
-$0.07 (-1.08%)
Updated
Aug 27, 04:59 PM (EDT)
Capitalization
400.05M
71 days until earnings call
GYRE
Price
$8.12
Change
+$0.36 (+4.64%)
Updated
Aug 27, 04:59 PM (EDT)
Capitalization
736.61M
77 days until earnings call
Interact to see
Advertisement

AURA vs GYRE

Header iconAURA vs GYRE Comparison
Open Charts AURA vs GYREBanner chart's image
Aura Biosciences
Price$6.43
Change-$0.07 (-1.08%)
Volume$645
Capitalization400.05M
Gyre Therapeutics
Price$8.12
Change+$0.36 (+4.64%)
Volume$2.32K
Capitalization736.61M
AURA vs GYRE Comparison Chart in %
Loading...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AURA vs. GYRE commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Buy and GYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (AURA: $6.44 vs. GYRE: $8.11)
Brand notoriety: AURA and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 70% vs. GYRE: 88%
Market capitalization -- AURA: $400.05M vs. GYRE: $736.61M
AURA [@Biotechnology] is valued at $400.05M. GYRE’s [@Biotechnology] market capitalization is $736.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 1 FA rating(s) are green whileGYRE’s FA Score has 1 green FA rating(s).

  • AURA’s FA Score: 1 green, 4 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, both AURA and GYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 2 TA indicator(s) are bullish while GYRE’s TA Score has 5 bullish TA indicator(s).

  • AURA’s TA Score: 2 bullish, 5 bearish.
  • GYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than AURA.

Price Growth

AURA (@Biotechnology) experienced а +1.10% price change this week, while GYRE (@Biotechnology) price change was +4.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was +19.75%, and the average quarterly price growth was +30.54%.

Reported Earning Dates

AURA is expected to report earnings on Nov 06, 2025.

GYRE is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($737M) has a higher market cap than AURA($400M). AURA YTD gains are higher at: -21.655 vs. GYRE (-35.868). GYRE has higher annual earnings (EBITDA): 11.5M vs. AURA (-107.51M). AURA has more cash in the bank: 177M vs. GYRE (54.4M). GYRE has less debt than AURA: GYRE (1.39M) vs AURA (18.1M). GYRE has higher revenues than AURA: GYRE (102M) vs AURA (0).
AURAGYREAURA / GYRE
Capitalization400M737M54%
EBITDA-107.51M11.5M-935%
Gain YTD-21.655-35.86860%
P/E RatioN/A405.50-
Revenue0102M-
Total Cash177M54.4M325%
Total Debt18.1M1.39M1,299%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
90
SMR RATING
1..100
84
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AURAGYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRIX14.610.03
+0.21%
NYLI CBRE Global Infrastructure Class I
SCDGX37.22N/A
N/A
DWS Core Equity S
WACLY200.04N/A
N/A
Wacoal Holdings Corp.
KLKLF0.15N/A
N/A
KIRKLAND LAKE DISCOVERIES CORP.
DMXCF0.73-0.16
-17.57%
District Metals Corp.

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-5.37%
SPRC - GYRE
38%
Loosely correlated
+0.24%
BEAM - GYRE
37%
Loosely correlated
+1.22%
RCKT - GYRE
36%
Loosely correlated
-4.24%
AURA - GYRE
36%
Loosely correlated
-0.31%
CRBU - GYRE
35%
Loosely correlated
+6.38%
More